ArticleJTO clinical and research reports2025

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50.

Yoshihito Kogure et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.